Dren Bio · Other
Pioneering the discovery and development of novel first-in-class antibody therapeutics for cancer and other serious diseases.
Amount
$350M
Round
Other
Valuation
—
Announced
May 2023
Investors
Lead investor
Juvia GroupParticipating investors
Notes
auto-discovered via firecrawl